Insights into non-alcoholic steatohepatitis (NASH)


Dublin, 05 May 2021 (GLOBE NEWSWIRE) – The “Global Non-alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028” the report was added to ResearchAndMarkets.com from offer.

According to this report, the global non-alcoholic steatohepatitis (NASH) biomarker market is expected to grow at a CAGR of 21.28% during the years 2021-2028.

The increasing occurrence of NASH in people, coupled with the increasing incidence rate of metabolic co-morbidities, is driving the examined market on a growth trajectory. In addition, increased awareness of non-alcoholic fatty liver disease opens new avenues for the NASH biomarker market during the projected period.

However, the side effects of NASH therapies, as well as the unavailability of specialized diagnostic tests for NAFLD, are hampering the expansion of the global market on a large scale.

REGIONAL OUTLOOK

The global market includes the Asia Pacific, North America, Latin America, Europe, Middle East and Africa regions.

The Asia-Pacific region is expected to observe the fastest growth rate of the non-alcoholic steatohepatitis biomarker market during the forecast period. The region’s growth can be attributed to advances in health infrastructure, skyrocketing NASH prevalence, and improving economic conditions. Along with this, the growing healthcare awareness in emerging economies, especially India and China, is expected to further influence the growth of the NASH biomarker market in the APAC region in the coming years.

COMPETITIVE OUTLOOK

Major companies involved in the non-alcoholic steatohepatitis (NASH) biomarker include Allergan, Merck & Co, Novartis AG, Viking Therapeutics, Bristol Myers Squibb Company, Novo Nordisk, Genfit SA, Pfizer Inc, Madrigal Pharmaceuticals, Gilead Sciences Inc, AstraZeneca , Zydus Cadila and Siemens Healthineers.

Allergan is engaged in the development, manufacture, marketing and distribution of specialty, biosimilar and nationwide products. Its product portfolio includes cenicriviroc which blocks two chemokine receptors involved in inflammatory and fibrogenic pathways. Phase 3 of this AURORA product plans to recruit a large number of patients suffering from NASH. Allergen operates in many regions, such as Asia-Pacific, Europe and Latin America, serving a large consumer base. Its headquarters are in Dublin, Ireland.

Main topics covered:

1. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market – Summary

2. Industry outlook
2.1. Key ideas
2.1.1. Request for NASH biomarkers
2.1.2. Unmet medical needs
2.2. Impact of COVID-19 on the market for non-alcoholic steatohepatitis (NASH) biomarkers
2.3. Porter’s Five Forces Analysis
2.3.1. The threat of new participants
2.3.2. Threat of substitute products
2.3.3. The bargaining power of buyers
2.3.4. Bargaining power of suppliers
2.3.5. Competitive rivalry
2.4. Market attractiveness index
2.5. Vendor Landscape
2.6. Key market strategies
2.6.1. Contracts and partnerships
2.6.2. Business expansions and divestitures
2.6.3. Acquisitions and mergers
2.6.4. Launch of new products
2.7. Market factors
2.7.1. Growing prevalence of NASH
2.7.2. Increased incidence rate of metabolic comorbidities
2.8. Market restrictions
2.8.1. Side Effects of NASH Therapeutics
2.8.2. Unavailability of the specialized diagnostic test for non-alcoholic fatty liver disease (Nafld)
2.9. Market opportunities
2.9.1. Growth opportunities in developing regions
2.9.2. Increased awareness of non-alcoholic fatty liver disease

3. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market – By Type
3.1. Serum biomarker
3.2. Biomarker of hepatic fibrosis
3.3. Apoptosis biomarker
3.4. Oxidative stress biomarker
3.5. Other types

4. Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market – By Sectors
4.1. Pharma & Cro Industry
4.2. Diagnostic laboratory
4.3. Academic research key
4.4. Hospital

5. Global Non-alcoholic Steatohepatitis (NASH) Biomarker Market – Regional Outlook
5.1. North America
5.1.1. Market by type
5.1.2. Market by verticals
5.1.3. Country analysis
5.1.3.1. United States
5.1.3.2. Canada
5.2. Europe
5.2.1. Market by type
5.2.2. Market by verticals
5.2.3. Country analysis
5.2.3.1. Germany
5.2.3.2. France
5.2.3.3. UK
5.2.3.4. Italy
5.2.3.5. Russia
5.2.3.6. Spain
5.2.3.7. The rest of europe
5.3. Asia Pacific
5.3.1. Market by type
5.3.2. Market by verticals
5.3.3. Country analysis
5.3.3.1. China
5.3.3.2. Japan
5.3.3.3. Australia and New Zealand
5.3.3.4. India
5.3.3.5. South Korea
5.3.3.6. ASEAN countries
5.3.3.7. Rest of Asia-Pacific
5.4. Latin America
5.4.1. Market by type
5.4.2. Market by verticals
5.4.3. Country analysis
5.4.3.1. Mexico
5.4.3.2. Brazil
5.4.3.3. Rest of Latin America
5.5. Middle East and Africa
5.5.1. Market by type
5.5.2. Market by verticals
5.5.3. Country analysis
5.5.3.1. Saudi Arabia
5.5.3.2. United Arab Emirates
5.5.3.3. turkey
5.5.3.4. South Africa
5.5.3.5. Rest of the Middle East and Africa

6. Competitive landscape
6.1. Allergan
6.2. Astrazeneca
6.3. Bristol Myers Squibb Company
6.4. Genfit Sa
6.5. Gilead Sciences Inc
6.6. Madrigal Pharmaceuticals
6.7. Merck & Co
6.8. Novartis AG
6.9. Novo Nordisk
6.10. Pfizer Inc
6.11. Siemens Healthineers
6.12. Viking Therapeutics
6.13. Zydus Cadila

7. Methodology and scope of the research
7.1. Scope of research and deliverables
7.1.1. Objectives of the study
7.1.2. Scope of the study
7.2. Data sources
7.2.1. Primary data sources
7.2.2. Secondary data sources
7.3. Research methodology
7.3.1. Assessment of the proposed market
7.3.2. Identification of data sources
7.3.3. Assessment of market determinants
7.3.4. Data gathering
7.3.5. Data validation and analysis

For more information on this report, visit https://www.researchandmarkets.com/r/d9bj5h


About Rhonda Lee

Check Also

How to cope – Cleveland Clinic

It starts with a beer, a glass of wine or a cocktail. Then there’s another…and …

Leave a Reply

Your email address will not be published.